The Association for the Accreditation of Human Research Protection Programs today announced that it has awarded accreditation to five more organizations
The Association for the Accreditation of Human Research Protection Programs today announced that it has awarded accreditation to five more organizations, including institutions in Seoul, Republic of Korea; Nanjing, China; Michigan; New York and Louisiana. The newly accredited organizations are:
“These latest accreditations demonstrate the increasing recognition that AAHRPP accreditation is the mark of excellence for human research protection programs, here and around the globe,” said Elyse Summers, AAHRPP president and CEO. “AAHRPP accreditation signifies an organization’s commitment to the highest level of research protections—all to the benefit of the research participants we are pledged to protect.”
AAHRPP accreditation is available to U.S. and international organizations that conduct biomedical, behavioral or social sciences research involving human participants. Accreditation decisions are made quarterly. They continue at a steady pace, reflecting strong interest in every sector of the research enterprise, in the U.S. and abroad.
To date, AAHRPP has accredited organizations in 46 states, Canada, China, India, Mexico, Republic of Korea, Singapore and Taiwan. All major U.S. independent institutional review boards have earned AAHRPP accreditation. In addition, more than 60 percent of U.S. research-intensive universities and 65 percent of U.S. medical schools are either AAHRPP accredited or have begun the accreditation process.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Pfizer Reports Strong Phase III Results for Hympavzi in Hemophilia Patients with Inhibitors
June 26th 2025The Phase III BASIS trial found that once-weekly subcutaneous Hympavzi reduced treated bleed rates by 93% in patients with hemophilia A or B with inhibitors, offering a promising new prophylactic option for a population with limited therapeutic choices.